Solar A/S
25.2.2021 15:38:13 CET | Globenewswire | Press release
Solar’s Executive Board and management team will be granted a total of 13,037 restricted shares in 2021 at a total market value of DKK 5.9m.
In accordance with Solar's remuneration policy, the Board of Directors decided to grant restricted shares to the Executive Board and management team in 2021.
Restricted shares are granted for no consideration and provide the holder with a right and an obligation to receive B shares at a nominal value of DKK 100. The grant price is fixed at DKK 456.39 based on the average price on Nasdaq Copenhagen the first 10 business days after publication of Annual Report 2020. A total amount of 13,037 restricted shares will be granted with a total market value of DKK 5.9m.
The restricted shares vest three years after the time of granting, meaning that this grant of shares vests in 2024. At this point, the holder may exercise the restricted share granting.
Solar’s Executive Board and management team has as of today, and in accordance with the program a total of 26,970 outstanding restricted shares, as 3,443 shares from the award in 2018 now has been settled with the participants.
General information on Solar’s incentive scheme is available on our website: www.solar.eu/investor/policies.
Contacts
Chairman of the Board of Directors Jens Borum
Tlf. +45 79 30 00 00
IR Director, Dennis Callesen - Tel. +45 29 92 18 11
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Jelenew24.3.2026 08:20:22 CET | Press release
JELENEW Opens New Store in Barcelona, Joining the Spanish Women’s Cycling Journey
Immutrin24.3.2026 08:00:00 CET | Press release
Immutrin raises £65 million ($87 million) Series A to develop next generation antibody therapy for ATTR amyloidosis
Harvia Oyj24.3.2026 08:00:00 CET | Press release
TRANSFER OF HARVIA’S OWN SHARES AS REWARDS UNDER INCENTIVE PROGRAM
ING Group24.3.2026 08:00:00 CET | Press release
Progress on share buyback programme
Sanofi Winthrop Industrie24.3.2026 07:30:00 CET | Press release
Press release: Availability of the Q1 2026 aide-mémoire
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
